15.1 vs 12.4, P =0.02; PCM: 11 .1 vs 8.7, P =0.04), after adjusting for important confounding factors. CONCLUSIONS: Beers criteria utility extended beyond direct measurementof a limited set of inappropriate prescribing practices by serving as a clinically meaningful proxy for other inappropriate practices. Using prescribing quality indicators to guide interventions should thus identify patients for comprehensive medication review, rather than identifying specific medication targets for discontinuation. Future research should exploreboth the quality measurement and the intervention targeting applications of the Beerscriteria, particularly when integrated with otherindicators.
P harmacotherapy is a crucialcomponent of medical care and the consequences of inappropriate prescribing are significant, with roughly 1.5million preventable adverse drugevents in theUS annually, at a cost in excess of $4 billion.' Efforts to improve prescribing quality rely on valid measures for initial assessment andongoing monitoring. Prescribing qualitymeasures areoften classified as explicit (criterion based) versus implicit (judgment based)." Explicitmeasures rely on fixed criteria thatapply uniformly to all patients and can therefore be computerized and easily determined for large patient samples. In contrast, implicit measures relyon clinical judgment to allow for theneeds of individual patients, but are also criticized for lacking structure andreliability. Moreover,implicitmeasures requireaccessto detailed clinical data and highly trained clinician assessors. For thesereasons, explicit measures are usually selected over implicit approaches in real-world applications.
One of the most widely used prescribing quality indicators is an explicitcompilation of medications determined by Authorinformation provided at end of text.
theannals.com BACKGROUNO: The Beers criteria are a compilation of medications deemed potentially inappropriate for older adults, widely used as a prescribing quality indicator. OBJECTIVE: To determine whether Beers criteria serve as a proxy measure for other formsof inappropriate prescribing, as measured by comprehensive implicit review.
METHODS: Data for patients 65 yearsand older were obtained from the Veterans Affairs Enhanced PharmacyOutpatient Clinic (EPOC) and the Iowa Medicaid Pharmaceutical Case Management(PCM) studies. Comprehensive measurement of prescribing quality was conducted using expert clinician review of medical recordsaccording to the Medication AppropriatenessIndex (MAl). MAl scores attributableto non-Bears medications were contrasted between patients who did and did not receive a Beerscriteria medication. RESULTS: Beers criteria medications accounted for 12.9% (EPOC) and 14.0% (PCM)of total MAl scores. Importantly, non-Beers MAl scoreswere significantly higher in patients receiving a Beers criteria medication in both studies (EPOC: expert consensus to be inappropriate for use in older adults, commonly known as the Beers criteria/" One major criticism is that these criteria represent only a small fraction of all possible inappropriate prescribing practices and associated adverse outcomes."? In one study, Beers criteria medications accounted for only 13.6% of drugs deemed inappropriate by implicit review and 14.6% of drugs targeted for intervention by a physician-pharmacist team." Similarly, only 3.6% of adverse event-related emergency department visits were due to Beers criteria medications, compared to 17.3% and 13.0% of such visits being due to warfarin and insulin, respectively," While these findings have been used to highlight the limitations of the Beers criteria, it is important to recognize that predicting adverse drug events is a very different application than measuring prescribing quality. While warfarin and insulin exposure may be important when predicting adverse drug events, their use in older adults is not considered potentially inappropriate, and therefore not suitable as prescribing quality measures. In contrast, Beers criteria comprise medications where risk generally outweighs benefit when used in older adults," It is reasonable to require a process measure of prescribing quality, such as Beers criteria, to be a risk factor for adverse drug events to establish validity. However, it is unreasonable to expect them to perform as well as other measures specifically designed for this purpose and does not diminish their value in measuring prescribing quality.
While an infrequent cause at the individual drug level, Beers criteria medications have been frequently associated with adverse event risk when examined at the patient level. 10 -17 For example, one study found only 6.0% of adverse drug events attributable to Beers criteria medications, yet patients who received these drugs were significantly more likely than those who did not to have an adverse drug event (35.0% vs 20.9%).14 Although Beers criteria medications did not account for many adverse events at the individual drug level, their utility may be higher at the patient level. In addition, the magnitude of association between Beers criteria medication exposure and adverse events is often diminished by adjusting for potential confounders.t-" These observations suggest that Beers criteria may serve as a proxy measure for other forms of inappropriate prescribing. That is, patients receiving a Beers criteria medication may be exposed to other inappropriate prescribing practices at higher rates, which collectively contribute to adverse event risk. While this may be seen as unwanted confounding from a causality perspective, this is an acceptable or even desirable property for a quality indicator. Strong correlations have been observed between quality indicators in related clinical areas, such as myocardial infarction and congestive heart failure." However, these relationships remain unclear for broadly defined pre-scribing indicators, which are not limited to specific disease states.
Therefore, the objective of this study was to determine whether Beers criteria are a proxy measure for other forms of inappropriate prescribing. We conducted replicate analyses using 2 independently collected patient samples, where inappropriate prescribing was measured by comprehensive implicit review according to the Medication Appropriateness Index (MAl). Total MAl scores attributable to non-Beers medications were compared between patients receiving and those not receiving a Beers criteria medication.
Methods

THE VETERANS AFFAIRS ENHANCED OUTPATIENT CLINIC STUDY
The EPOC (Enhanced Pharmacy Outpatient Clinic) study enrolled veterans 65 years and older seen in primary care clinics at the Iowa City Veterans Affairs (VA) Medical Center and receiving at least 5 prescription medications. Patients were randomized to receive either a pharmacist-physician collaborative intervention or usual care." The goal of the intervention was to improve prescribing quality and medication safety. This sample has been used in several prior studies examining the interrelationships between various measures of inappropriate prescribing, including the MAl, an implicit measure, and the explicit Beers criteria. 7 ,8,20,21Of 532 patients enrolled in EPOC, a convenience subset of 240 received a baseline MAl evaluation; this subset forms the sample for this analysis. These individuals did not differ significantly from patients without baseline MAl evaluations on key characteristics including age, sex, race, education, medical comorbidity, or Beers medication frequency," THE IOWA MEDICAID PHARMACEUTICAL CASE
MANAGEMENT STUDY
The PCM (Iowa Medicaid Pharmaceutical Case Management) study examined the effectiveness of reimbursing community pharmacists to provide outpatient pharmaceutical case management services." Patients were noninstitutionalized Medicaid-eligible individuals taking at least 4 chronic medications. Of 2211 individuals eligible to receive the intervention, 524 received PCM services. Of these, 507 (97%) had sufficient baseline clinical records to allow an evaluation of prescribing appropriateness with the MAL After restricting the sample to individuals aged 65 years and older for whom the Beers criteria are applicable, 167 patients were available for this analysis.
INAPPROPRIATE PRESCRIBING MEASURES
BeersCriteria as a Proxyfor Inappropriate Prescribing of OtherMedications AmongOlder Adults
STATISTICAL ANALYSIS
Inappropriate prescribing was assessed at enrollment in both studiesusing the MAI. 23 The MAl includes 10 items assessing multiple domains and is generally considered amongthe best available tools for implicit measurement of inappropriate prescribing. Examples of MAl itemsinclude the presence of drug-disease interactions, incorrect dosing, and therapeutic duplication. Eachof the 10items wasdeterminedto be appropriate or inappropriate by expertclinical judgmentbased on detailed review of all available clinical records.MAl ratingsfor both studies in this analysis were completed by a research pharmacist. After applying standard scoring weights, MAl scores range from 0 to 18 for each medication and patient-level scoresare generated by summing medication scores across the regimen. High MAl scoresreflect increasing levels of inappropriate prescribing. MAl score differences of approximately 2 points are generallyconsidered clinically meaningful.f-" The MAl has been shownto have excellent interrater (K =0.88) and intrarater (K = 0.92) reliability," In addition to total scores, we calcu-lated2 patient-level subscores for (1) Beers criteria medications (Beers MAl score) and (2) all other criteria medicationsin theregimen (non-Beers MAl score).
Inappropriate prescribing was also assessed in both studies according to Beerscriteria." The Beerscriteria represent a compilation of medications determined by expert panel to have an unfavorable risk-to-benefit ratio when used in older adults. These criteria include medications consideredinappropriate independent of other considerations (eg, propoxyphene), inappropriate abovecertaindosage limits(eg, lorazepam >3 mg), and inappropriate given specific concurrent medical conditions (eg,tricyclic antidepressants in patients with syncope or falls). Applying Beers criteriadoes not account for patient-specific decision-making and assumes these medications are alwaysinappropriate for use in elderly individuals.Therefore, the term potentially inappropriateprescribing is often used when referring to the Beers criteria and other similar explicit measures.The Beers criteria were originally published in 1991,with updates in 1997 and 2003. 4 MAl scores were compared between patientsexposed versus those unexposed to Beers criteria medications, using a general linear model (GLM) approach.SAS procedure GLM version 9.2 (SAS Institute Inc., Cary,NC) was used to generate the test statisticcomparingthese groups (F test), adjustingfor age and sex. Furtheradjustment for medical comorbidity was conducted in a sensitivity analysis using EPOCstudydata," However, medical comorbidity did not affect the models and was not available for the PCM study, so was not included in the final analysis. A ttest was used to compare the number of drugs between groups. An exploratory subanalysiswas conducted comparing non-Beers MAl scoresfor each of the 10 individual MAl items between patients exposed and thoseunexposed to Beers criteria medications. The purpose of the subanalysis was to examine whether patients receiving Beerscriteria medications wereat risk for specific aspects of inappropriate prescribing. Neitherthe EPOC nor PCM study was powered for this purpose, and the subanalysis should be considered exploratory. Because item-level MAl scores are not normally distributed, the nonparametric Wilcoxon rank sum test was used to make comparisons between Beers medication exposed and unexposed groups.In addition to individual items, the subanalysis included an alternative algorithm for scoring the MAl that was created to assess risk for adverse drugevents,"
All analyses were conducted using SAS procedure GLM (version 9.2).Data fromthe EPOCand PCM studies wereexamined separately using identical methods. As the purpose of including data from these2 studies was purely for replication,no statistical comparisons were made between them. Our study was approvedby the Institutional Review Boardof the University of Iowa and Research and Development Committee at the IowaCity VA Health Care System.
Results
PATIENTS
Patientcharacteristics for the 2 analysis samples are descriptively contrasted in Table 1 . EPOC study patients were predominantly men (98.3%), with a mean (SO) age of 74.6 (5.4)years.PCM study patients had a similarmean age of 76.4 (7.5), but proportionately fewer men (13.8%). Comparisons of MAl scores between patients exposed and those unexposed to Beers criteria medications are presented in Table 2 . Significant elevations were observed among patients exposed to a Beers criteria medication, wheretotalMAl scoreswereover 50% higherin the EPOC study and nearly doubled in the PCM study. A substantial portion of this elevation was directly attributable to Beers criteria medications. As shown inTable 2, mean MAl scores related to Beers medications in the exposed groupwere4.6
in the EPOCstudy and 4.9 in the PCM study. The contributionof these drugsto total~AI scores wasremoved to generate patient-level MAl scoresfor non-Beers medications. Non-Beers MAl scores were significantly higher in patients exposed to Beers criteria medication in both studies, a difference of 2.7 in the EPOe study and 2.4 in the PCM study (Table 2) . Thus, patients exposed to a Beers criteria medication were at increased risk for inappropriate prescribing of other medications. The numberof non-Beers medications was notsignificantly different between Beers medication exposed versus unexposed patients in either study ( Table 2 ). An exploratory subanalysis of the 10 individual MAl items was conducted, again comparing patients exposed versus those unexposed to Beers criteria medications ( Table 3 ). Each MAl item was scored at the patient level across all non-Beers medications, using thestandard weights presented in Table3. In the EPOC study, alllO items were numerically higher among patients taking Beers criteria medication, indicating a higher level of inappropriate prescribing. The 2 itemsthat reached the threshold for statistical significance were duration of use and correct directions for use. Similar results wereseenin thePCM study. where nearly all items demonstrated higher levels of inappropriateness among patients receiving Beerscriteria medications. The drug-drug interaction and dosageitems reached statistical significance and thecostand practical directions for useitems approached significance in thisexploratory analysis.The modified MAl scoring algorithm also approached statistical significance, withconsistent fmdings between studies.
Discussion
Beers criteria medicationsdirectly accountedfor 12.9-14.0% of total inappropriate prescribing in older adults,as comprehensively measured by the MAl, with consistent findings drawn from 2 independently collected patient samples. In keeping with prior criticism, using Beers criteria as a measurement tool thus failed to capture more than 85% of inappropriate prescribing in older adults.?" However, this critique is limited to a drug-level perspective and does not consider the potential for Beers criteria to serve as a proxy for other inappropriate prescribing practices when applied at higher aggregate levels, such as the level of patient or facility. Therefore, the focus of this analysis was to determine whether patients exposed to Beers criteria medications were at increased risk for other forms of inappropriate prescribing. Our novel finding was supported by 2 independent samples, where inappropriate prescribing scores attributable to non-Beers criteria medications were significantly higher in patients exposed to Beers criteria medications. The magnitude of this difference was 2.4-2.7 points on the MAl, which is above the threshold generally considered clinically significant. Examination of individual MAl items was generally consistent with the overall findings. These studies were not designed and powered for this level of analysis, and the fmdings should be considered exploratory. With this caveat in mind, the general trend was toward increases in inappropriate prescribing practices among patients receiving a Beers criteria medication. Some individual items reached or approached statistical significance, but were not consistent between studies. We also examined an alternative MAl scoring algorithm developed specifically to predict adverse drug events, a clinically meaningful outcome."
While not statistically significant in this exploratory analysis, the findings were consistent between studies and suggested that patients receiving Beers criteria medications may be at increased risk for adverse drug events. Taken together, we interpret these findings as Beers criteria medication exposure being broadly associated with other inappropriate prescribing practices and not linked to any specific practice.
The observation of a clinically meaningful association between a measured quality indicator and typically unmeasured aspects of quality has important implications for health care quality measurement and intervention. Such associations are beneficial from a measurement perspective since aspects of quality that are impractical to adequately measure may be indirectly accounted for when making comparisons across providers or facilities. Ideally, a useful quality indicator should provide a suitable intervention target to enable providers, facilities, and health care systems to demonstrate improvement. From this intervention perspective, our findings highlight the limitations of using quality indicators as isolated targets. Interventions focused exclusively on reducing Beers criteria medication use would miss an opportunity to improve other aspects of inappropriate prescribing that are disproportionately common among individuals who receive these medications. Instead, using Beers criteria to identify patients for a comprehensive medication review would likely generate a more meaningful improvement in quality. A particular strength of this analysis is the replication of key findings across 2 independently collected patient samples. Both samples included older adults with complex medication regimens and multiple medical comorbidities. However, these groups differed in several important ways. The EPOC study was conducted in a single outpatient VA primary care clinic and involved principally men. In contrast, the PCM study was conducted in the community pharmacy setting, involved multiple practice sites, and enrolled Medicaid-eligible adults, who were mostly women. Despite these differences, the results were consistent across both studies.
There are a number of limitations that need to be considered. First, it is unclear whether these findings can be generalized to other patient groups, particularly those with less complicated medication regimens. Second, geographic variation in Beers criteria frequency has been documented and it is possible that the results from these studies, both conducted in a single state, may not apply to other regions." Third, different versions of the Beers criteria were used in the 2 cohorts, thus preventing direct comparison between the groups. However, the consistent findings between studies support the general premise of Beers criteria serving as a general marker of prescribing quality, regardless of which version is used.
An additional consideration is how to address the impact of number of medications on these findings. While the number of non-Beers medications was not significantly different between patients who received and did not receive a Beers medication, these groups differed numerically by approximately I medication in both studies. We did not adjust for number of medications in our statistical models for 2 important reasons. First, we were not attempting to establish a causal pathway for Beers criteria medication exposure leading to other forms of inappropriate prescribing. This stands in contrast to validation studies attempting to causally link Beers medication exposure and risk for adverse drug events, for example, where adjustment for number of medications may be more appropriate.' Rather, in examining Beers criteria as a proxy for other forms of inappropriate prescribing it is expected that some of the association may be non-causal, but that does not impair its function as a proxy measure. The second reason for not adjusting for number of medications is that some forms of inappropriate prescribing directly produce additional medications. For example, 2 items included on the MAl are therapeutic duplication and drug use without indication. If I of 2 hypothetically identical patients is exposed to these inappropriate prescribing practices, the result will be an additional medication in the patient's regimen that would not be present in the other individual's regimen. In such cases, including number of medications would overadjust the model, thereby eliminating the precise effect that the analysis was attempting to measure.
Safe and effective medication use is an important aspect of health care and efforts to improve prescribing quality require valid and useful measures. Our findings demonstrate that the utility of Beers criteria extends beyond the direct measurement of a limited set of inappropriate prescribing practices by serving as a clinically meaningful proxy for other forms of inappropriate prescribing. Thus, when used to guide interventions, prescribing quality indicators may be more optimally used to identify individuals for comprehensive medication review, rather than merely as specific targets for discontinuation. Applied at a higher level, such indicators could be used to create clinic-or facilitylevel benchmarks to identify locations of care that might benefit most from intervention. Future research should explore both the quality measurement and the intervention targeting applications of the Beers criteria, particularly when integrated with other indicators. Quality-oriented research should emphasize how multiple indicators may be combined to provide more comprehensive measurement of prescribing quality. Intervention-oriented research should explore how quality indicators may be integrated with risk-based indicators (eg, number of drugs, drug requiring therapeutic drug monitoring) to target patients most likely to benefit from interventions of varying types and intensity.
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EXTRAcro TRASFONDO: Los criterios Beers son una recopilaci6nde medicamentos consideradospotencialmente inadecuadospara adultos de edad avanzada y son usados extensamente como un indicadorde la calidad de prescripci6n.
OBJETIVO: Determinar si los criterios Beers sirven como una medida sustituta para otras forrnas de prescripci6ninadecuada, segun medidas por una revisi6n implfcitaextensa, MtTooos: Datos de pacientes de 65 aiios y mayores fueron obtenidos de estudios del VA Enhanced Pharmacy OutpatientClinic (EPOC) y del Iowa Medicaid Pharmaceutical Case Management (PCM). La medida total de la calidad de prescripci6nfue conducida usando peritos medicos para la revisi6n de expedientes medicos de acuerdo con el lndice de Propiedad del Medicamento (MAl). Los resultados de MAl atribuibles a medicamentos no-Beers (MAl no-Beers)fueron contrastados entre pacientes que reeibieron y pacientes que no reeibieron un medicamento de criterio Beers.
RESULTADOS: Los medicamentos de los criterios Beers representaron un 12.9% y un 14.0% del total de los resultados de MAl en los 2 estudios. Mas importante, los resultados de MAl no-Beersfueronsignifieativamente mas altos en pacientes recibiendo un medicarnentode los criterios Beers enarnbosestudios(EPOC: 15.1 vs 12.4,p=0.02;PCM: 11.1 vs8.7,p= 0.04), despues de ajustar parafactores de confusi6n importantes. CONCI.USIONES: La utilidadde los criterios Beers se extendio mas alla de la medici6n directa de un grupo Iimitadode practices de prescripci6n inadecuadas aI servir como un sustituto c1fnicamente significativopara otras practicas inadecuadas.EI uso d~indicadores d~la c~idad de. prescripci6npara dirigir las mtervencionesdebe asf.Iden~fi car pa~l~ntes para revisiones totalesde medicarnentos,~n vez de identificarobjetivos especfficospara descontinuar.Investi gaci on~s~turas debe~explonu: tanto la medici6n de la calidad como las aplicacionesde la intervencion de selecci6ndel objetivo de los criterios Beers, en especial cuando se irnegrancon otros indicadores.
